TNDM.OQ
Latest Trade
93.64USDChange
0.34(+0.36%)Volume
49,121Today's Range
-
95.0052 Week Range
-
123.71As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 93.30 |
|---|---|
Open | 94.05 |
Volume | 49,121 |
3M AVG Volume | 17.33 |
Today's High | 95.00 |
Today's Low | 93.13 |
52 Week High | 123.71 |
52 Week Low | 43.76 |
Shares Out (MIL) | 62.19 |
Market Cap (MIL) | 5,704.49 |
Forward P/E | -127.51 |
Dividend (Yield %) | -- |
Tandem Diabetes Care Announces Q3 Sales $123.6 Mln
Tandem Diabetes Reports Qtrly Net Loss Per Share Of $0.45
Medtronic And Tandem Diabetes Care Enter Into Patent Cross-License Agreement
Tandem Diabetes Care, Inc. is a medical device company engaged in the designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing, sales and support activities principally focus on its flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), and its product offerings. The t:slim X2 is based on its technology platform and is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. Its products also include Basal-IQ technology and Control-IQ technology. The Basal-IQ technology is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. The Control-IQ technology is a hybrid-closed loop feature, designed to help increase a user's time in targeted glycemic range.
Industry
Medical Equipment & Supplies
Contact Info
11075 Roselle St
SAN DIEGO, CA
92121-1204
United States
+1.858.3666900
https://www.tandemdiabetes.com/Executive Leadership
Kim D. Blickenstaff
Chairman of the Board
John F. Sheridan
President, Chief Executive Officer, Director
Leigh A. Vosseller
Chief Financial Officer, Executive Vice President, Treasurer
Susan M. Morrison
Executive Vice President, Chief Administrative Officer
David B. Berger
Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 12.99 |
Price To Book (MRQ) | 17.45 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 60.98 |
LT Debt To Equity (MRQ) | 60.98 |
Return on Investment (TTM) | -12.83 |
Return on Equity (TTM) | -10.09 |
* MEDTRONIC AND TANDEM DIABETES CARE ENTER INTO PATENT CROSS-LICENSE AGREEMENT
* ABBOTT - COS PARTNER TO INTEGRATE ABBOTT'S FREESTYLE LIBRE CONTINUOUS GLUCOSE MONITORING TECHNOLOGY WITH TANDEM'S INSULIN DELIVERY PRODUCTS Source text for Eikon: Further company coverage:
* TANDEM DIABETES CARE ACQUIRES SUGARMATE, A POPULAR MOBILE APP FOR PEOPLE WITH DIABETES
* TANDEM DIABETES CARE ANNOUNCES EXPANDED PEDIATRIC INDICATION OF THE T:SLIM X2 INSULIN PUMP WITH CONTROL-IQ ADVANCED HYBRID CLOSED-LOOP TECHNOLOGY Source text for Eikon: Further company coverage:
* TANDEM DIABETES CARE - RICHARD P. VALENCIA NOTIFIED HE INTENDS TO COMMENCE SERVICE AS CHAIRMAN & CEO OF A PRIVATELY HELD COMPANY
* TANDEM DIABETES CARE ANNOUNCES PRICING OF $250.0 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2025
* TANDEM DIABETES CARE ANNOUNCES PROPOSED OFFERING OF $250.0 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2025
* TANDEM DIABETES CARE ANNOUNCES SECURITY INCIDENT WITH FIVE EMPLOYEE EMAIL ACCOUNTS
* TANDEM DIABETES CARE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND 2020 FINANCIAL GUIDANCE
The U.S. Food and Drug Administration on Friday granted approval for Tandem Diabetes Care's software program that uses readings from a continuous glucose monitor to predict and deliver corrective doses of insulin to patients using the company's t:slim X2 insulin pump.
The U.S. Food and Drug Administration on Friday granted approval for Tandem Diabetes Care's software program that uses readings from a continuous glucose monitor to predict and deliver corrective doses of insulin to patients using the company's t:slim X2 insulin pump.
* TANDEM DIABETES CARE-ANNOUNCED RECEIPT OF CE MARK APPROVAL FOR T:SLIM X2 INSULIN PUMP WITH DEXCOM G5® MOBILE CONTINUOUS GLUCOSE MONITORING INTEGRATION
* TANDEM DIABETES CARE INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source : https://bit.ly/2JtPqwk Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* TANDEM DIABETES CARE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
* TANDEM DIABETES CARE SAYS ANNOUNCES AGREEMENTS FOR DISTRIBUTION OF INSULIN PUMP PRODUCTS IN AUSTRALIA AND NEW ZEALAND Source text for Eikon: Further company coverage:
* TANDEM DIABETES CARE ANNOUNCES PRELIMINARY FIRST QUARTER 2018 RESULTS
* TANDEM DIABETES CARE AND MOVI SPA ANNOUNCE AGREEMENT FOR DISTRIBUTION OF INSULIN PUMP PRODUCTS IN ITALY
* SALES FOR Q1 OF 2018 ARE ESTIMATED TO BE 18 PERCENT - 19 PERCENT OF ANNUAL SALES
* TANDEM DIABETES CARE APPLIES FOR HEALTH CANADA MEDICAL DEVICE LICENSE
* TANDEM DIABETES CARE FILES FOR OFFERING OF 13.5 MILLION SHARES OF CO'S COMMON STOCK, PAR VALUE $0.001 PER SHARE - SEC FILING Source text: (http://bit.ly/2nmA5Fh) Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.